Re the share price: 

I think the problem is ---

1. It's new science, which the market doesn't understand (fair enough!). But the fact is it's very sound and very solid. That's why the FDA is supporting it.

3. DM has a record of making overoptimistic predictions which have hit his credibility. He also does not come across as a go-getting science-savvy entrepreneur. His science statements often lack conviction even when they are sound. 

4. DM is paid such a ridiculously high salary for looking after a one drug portfolio there's little incentive to push on as fast as possible. 

It's frustrating, but the drug has huge potential and I feel confident we'll get there in the end. 

All imo.